"Questions remain on how to
select patients for aducanumab, when to start treatment, how to monitor
patients during treatment, and how long to treat. It is expected there will be
a lot of interest from patients and/or their caregivers."
— April Kunze, senior director of clinical formulary development
and trend management strategy at Prime Therapeutics, talked with AIS's RADAR on Drug Benefits about
how the industry is reacting to the FDA's approval of Biogen Inc.'s Aduhelm.
No comments:
Post a Comment